The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Open accessAbstract
HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This approach has shown efficacy in colon cancer and NSCLC patients with mutant KRAS G12D and HLA-C*08:02 expression [88].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
In the citing paper
“CD8+ TILs and TCRs in CD4+ T cells have been found to specifically recognize KRAS-related mutations, which can be further used to engineer T cells.604,605”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [604]
In the citing paper
“As noted above, peptides derived from KRASG12 variants193,194, and also from KRASQ61H/L/R (ref.198), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRASG12D-mutant CRC from whom they had been isolated193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.193, who identified CD8+ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRASG12D.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Using CD8+ T cells that were reactive to KRASG12D mutant, a patient with CRC experienced prolonged partial response [64].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [64]
In the citing paper
“It was found that CD8+ T cells, possessing HLA-C08:02-restricted T-cell receptors, specifically recognize the mutant KRASG12D.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Following the intravenous administration of expanding TCRs in an ex vivo environment, a complete response was observed in lung lesions, resulting in prolonged PFS.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“A recent publication presented the relationship between the KRASG12D mutation and TCRs in a patient diagnosed with metastatic mCRC with lung metastasis [106].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Despite the rarity of HLA-C*08:02, this study demonstrated the promise of T-cell–based immunotherapy for targeting KRASG12D and HLA-C*08:02.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“Tran and colleagues described a case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRASG12D, which was restricted to the major histocompatibility complex class I allele HLA-C*08:02 (44).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citationAllele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,192
Cited by
Sorted by citations
Items 201–300 of 1,002
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Anderson, P., Aptsiauri, N., Ruiz-Cabello, F., & Garrido, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00634-7 · Cited by 107
T-cell-based immunotherapy in colorectal cancer
Feng, M., Zhao, Z., Yang, M., Ji, J., & Zhu, D. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.040 · Cited by 108
Engineered T cell therapy for viral and non-viral epithelial cancers
Norberg, S. M., & Hinrichs, C. S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.016 · Cited by 108
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Şahin, İ. H., Askan, G., Hu, Z., & O'Reilly, E. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx503 · Cited by 108
Dey, A., Mitra, A., Pathak, S., Prasad, S. V., Sun-Zhang, A., Zhang, H., Sun, X., & Banerjee, A. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231178403 · Cited by 108
Therapeutic cancer vaccines: From initial findings to prospects
Song, Q., Zhang, C.-D., & Wu, X.-H. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.01.011 · Cited by 106
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Bannoura, S. F., Uddin, M. H., Nagasaka, M., Fazili, F., Hallak, M. N. A., Philip, P. A., El‐Rayes, B. F., & Azmi, A. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09990-2 · Cited by 112
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
Chang, Z., & Chen, Y. Y. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.002 · Cited by 105
Heinrich, S., Craig, A. J., Ma, L., Heinrich, B., Greten, T. F., & Wang, X. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.036 · Cited by 105
Combinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 107
CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia
Biernacki, M. A., Foster, K. A., Woodward, K. B., Coon, M. E., Cummings, C. C., Cunningham, T. M., Dossa, R. G., Brault, M., Stokke, J. L., Olsen, T. M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137723 · Cited by 104
Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes
Isaeva, O. I., Sharonov, G. V., Serebrovskaya, E. O., Turchaninova, M. A., Zaretsky, A. R., Shugay, M., & Chudakov, D. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0747-1 · Cited by 102
An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors
Lu, Y., Zheng, Z., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Li, Y. F., Ray, S., Franco, Z., Bliskovsky, V. V., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.018 · Cited by 105
Self-citationSteentoft, C., Migliorini, D., King-Peoples, T. R., Mandel, U., June, C. H., & Posey, A. D. (2018) · Glycobiology · doi:10.1093/glycob/cwy008 · Cited by 102
KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
Lu, D., Chen, Y., Jiang, M., Wang, J., Li, Y., Ma, K., Sun, W., Zheng, X., Qi, J., Jin, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42010-1 · Cited by 101
Metabolic reprograming of anti-tumor immunity
Sukumar, M., Kishton, R. J., & Restifo, N. P. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.03.011 · Cited by 103
Agrawal, L., Engel, K. B., Greytak, S. R., & Moore, H. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.008 · Cited by 104
Zhou, C., Li, W., Zhenxing, L., Wu, X., Cheng, S., Peng, J., Zeng, K., Li, W., Lan, P., Yang, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44779-1 · Cited by 108
Molecular genetics and cellular events of K-Ras-driven tumorigenesis
Jinesh, G. G., Sambandam, V., Vijayaraghavan, S., Balaji, K., & Mukherjee, S. (2017) · Oncogene · doi:10.1038/onc.2017.377 · Cited by 100
The Origin and Immune Recognition of Tumor-Specific Antigens
Apavaloaei, A., Hardy, M., Thibault, P., & Perreault, C. (2020) · Cancers · doi:10.3390/cancers12092607 · Cited by 95
Monberg, T. J., Borch, T. H., Svane, I. M., & Donia, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2428 · Cited by 99
Consensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 104
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 106
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 107
Mutation position is an important determinant for predicting cancer neoantigens
Capietto, A.-H., Jhunjhunwala, S., Pollock, S. B., Lupardus, P. J., Wong, J., Hänsch, L., Cevallos, J., Chestnut, Y., Fernandez, A., Lounsbury, N., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190179 · Cited by 99
KRAS G12C–Mutant Non–Small Cell Lung Cancer
Veluswamy, R., Mack, P. C., Houldsworth, J., Elkhouly, E., & Hirsch, F. R. (2021) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.02.002 · Cited by 96
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 95
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen, N. D., Wang, M., Rubinstein, J. C., Olino, K. L., Clune, J. E., Ariyan, S., Cha, C. H., Weiss, S. A., Kluger, H. M., & Sznol, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000341 · Cited by 95
Unveiling the role of KRAS in tumor immune microenvironment
Xu, M., Zhao, X., Wen, T., & Qu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116058 · Cited by 93
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
Rech, A. J., Balli, D., Mantero, A. M. A., Ishwaran, H., Nathanson, K. L., Stanger, B. Z., & Vonderheide, R. H. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0559 · Cited by 93
Kather, J. N., & Halama, N. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0441-6 · Cited by 95
Warner, A. B., Hamid, O., Komanduri, K. V., Amaria, R. N., Butler, M. O., Haanen, J. B. A. G., Nikiforow, S., Puzanov, I. J., Sarnaik, A. A., Bishop, M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008735 · Cited by 91
Personalized T cell-mediated cancer immunotherapy: progress and challenges
Bethune, M. T., & Joglekar, A. V. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.024 · Cited by 91
Trials and tribulations of pancreatic cancer immunotherapy
Principe, D. R., Korc, M., Kamath, S. D., Munshi, H. G., & Rana, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.031 · Cited by 95
Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy
Yi, F., Frazzette, N., Cruz, A. C., Klebanoff, C. A., & Siegel, R. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.05.004 · Cited by 89
Gartner, J. J., Parkhurst, M. R., Gros, A., Tran, E., Jafferji, M. S., Copeland, A. R., Hanada, K., Zacharakis, N., Lalani, A., Krishna, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00197-6 · Cited by 90
Self-citationMutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Perumal, D., Imai, N., Laganà, A., Finnigan, J. P., Melnekoff, D. T., Leshchenko, V. V., Solovyov, A., Madduri, D., Chari, A., Cho, H. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2309 · Cited by 92
Burrack, A. L., Spartz, E. J., Raynor, J. F., Wang, I., Olson, M. A., & Stromnes, I. M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.059 · Cited by 89
The current clinical landscape of personalized cancer vaccines
Fritah, H., Rovelli, R., Chiang, C. L.-L., & Kandalaft, L. E. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102383 · Cited by 87
Organoid Models for Precision Cancer Immunotherapy
Sun, C., Lan, H., Fang, X., Yang, X., & Jin, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.770465 · Cited by 90
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 98
Müller, M., Gfeller, D., Coukos, G., & Bassani‐Sternberg, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01367 · Cited by 87
Yossef, R., Krishna, S., Sindiri, S., Lowery, F. J., Copeland, A. R., Gartner, J. J., Parkhurst, M. R., Parikh, N. B., Hitscherich, K. J., Levi, S. T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.005 · Cited by 86
Self-citationLee, H. J., Kim, Y., Sim, C. K., Heo, S., Song, I. H., Park, H. S., Park, S. Y., Bang, W. S., Park, I. A., Lee, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23007 · Cited by 86
Guo, Z., Yuan, Y., Chen, C., Lin, J., Ma, Q., Liu, G., Gao, Y. L., Huang, Y., Chen, L., Chen, L., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00279-3 · Cited by 86
Krishna, S., Ulrich, P. R., Wilson, E., Parikh, F., Narang, P., Yang, S., Read, A. K., Kim‐Schulze, S., Park, J. G., Posner, M. R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0163 · Cited by 85
Yu, H., Chen, Z., Ballman, K. V., Watson, M. A., Govindan, R., Lanc, I., Beer, D. G., Bueno, R., Chirieac, L. R., Chui, M. H., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.006 · Cited by 85
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., Cortes, E., Wong, L.-P., Yan, L., Long, M. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0629-6 · Cited by 85
Lin, Y., Peng, L., Dong, L., Liu, D., Ma, J., Lin, J., Chen, X., Lin, P., Song, G., Zhang, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1640 · Cited by 84
Self-citationPérez-Baños, A., Gleisner, M. A., Flores, I., Pereda, C., Navarrete, M., Araya, J. P., Navarro, G., Quezada-Monrás, C., Tittarelli, A., & Salazar‐Onfray, F. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02327-6 · Cited by 90
Therapeutic cancer vaccine: building the future from lessons of the past
Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., & Tartour, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0691-z · Cited by 85
Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood
Peng, S., Zaretsky, J. M., Ng, A. H. C., Chour, W., Bethune, M. T., Choi, J., Hsu, A. C., Holman, E. A., Ding, X., Guo, K. L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.106 · Cited by 84
Wang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 85
Huang, Q., Zhang, H., Hai, J., Socinski, M. A., Lim, E. K. S., Chen, H., & Stebbing, J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1396403 · Cited by 82
Targeted Therapies for Pancreatic Cancer
Amanam, I. U., & Chung, V. M. (2018) · Cancers · doi:10.3390/cancers10020036 · Cited by 85
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
Blaquier, J. B., Ortiz‐Cuaran, S., Ricciuti, B., Mezquita, L., Cardona, A. F., & Recondo, G. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1912 · Cited by 82
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade
Palmer, D. C., Webber, B. R., Patel, Y. K., Johnson, M. J., Kariya, C. M., Lahr, W. S., Parkhurst, M. R., Gartner, J. J., Prickett, T. D., Lowery, F. J., et al. (2022) · Med · doi:10.1016/j.medj.2022.07.008 · Cited by 82
Self-citationActivation and expansion of human T cells using artificial antigen-presenting cell scaffolds
Zhang, D. K. Y., Cheung, A. S., & Mooney, D. J. (2020) · Nature Protocols · doi:10.1038/s41596-019-0249-0 · Cited by 82
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 82
Direct Detection and Quantification of Neoantigens
Wang, Q., Douglass, J., Hwang, M. S., Hsiue, E. H.-C., Mog, B. J., Zhang, M., Papadopoulos, N., Kinzler, K. W., Zhou, S., & Vogelstein, B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0107 · Cited by 81
Targeting loss of heterozygosity for cancer-specific immunotherapy
Hwang, M. S., Mog, B. J., Douglass, J., Pearlman, A. H., Hsiue, E. H.-C., Paul, S., DiNapoli, S. R., Konig, M. F., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022410118 · Cited by 80
CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success
Long, K. B., Young, R. M., Boesteanu, A. C., Suhoski, M. M., Melenhorst, J. J., Lacey, S. F., Degaramo, D. A., Levine, B. L., & Fraietta, J. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02740 · Cited by 80
Lanfredini, S., Thapa, A., & O’Neill, E. E. (2019) · Biochemical Society Transactions · doi:10.1042/bst20170521 · Cited by 78
Zhou, B., Gao, Y., Zhang, P., & Chu, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693609 · Cited by 81
Nagasaka, M., Potugari, B. R., Nguyen, A., Sukari, A. W., Azmi, A. S., & Ou, S. I. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102309 · Cited by 80
Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen
Wu, D., Gallagher, D. T., Gowthaman, R., Pierce, B. G., & Mariuzza, R. A. (2020) · Nature Communications · doi:10.1038/s41467-020-16755-y · Cited by 78
Targeting neoantigens for cancer immunotherapy
Zhao, X., Pan, X., Wang, Y., & Zhang, Y. (2021) · Biomarker Research · doi:10.1186/s40364-021-00315-7 · Cited by 78
Fundamental immune–oncogenicity trade-offs define driver mutation fitness
Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z. M., de Andrade, K. C., Bajorin, D. F., Bandlamudi, C., Callahan, M. K., Funt, S. A., Hadrup, S. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04696-z · Cited by 81
Brightman, S. E., Becker, A., Thota, R. R., Naradikian, M. S., Chihab, L. Y., Zavala, K. S., Premlal, A. L. R., Griswold, R. Q., Dolina, J. S., Cohen, E. E. W., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01543-9 · Cited by 79
Leroux, C., & Konstantinidou, G. (2021) · Cancers · doi:10.3390/cancers13040799 · Cited by 80
Motta, R., Cabezas-Camarero, S., Mattos, C. T., Riquelme, A., Calle, A., Figueroa, A., & Sotelo, M. J. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202104.016 · Cited by 76
T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy
Frank, M. L., Lu, K. J., Erdogan, C., Han, Y., HU, J. L., Wang, T., Heymach, J. V., Zhang, J. J., & Reuben, A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2469 · Cited by 77
CAR-T cell therapy for the treatment of adult high-grade gliomas
Park, S., Maus, M. V., & Choi, B. D. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00753-0 · Cited by 81
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75
Future Challenges in Cancer Resistance to Immunotherapy
van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 76
Granhøj, J. S., Jensen, A. W. P., Presti, M., Met, Ö., Svane, I. M., & Donia, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2064711 · Cited by 76
Qin, Y. W., Ekmekçioglu, S., Forget, M., Székvölgyi, L., Hwu, P., Grimm, E. A., Jazaeri, A. A., & Roszik, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00689 · Cited by 75
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Molina‐Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 76
Qayoom, H., Sofi, S., & Mir, M. A. (2023) · Immunologic Research · doi:10.1007/s12026-023-09376-2 · Cited by 74
Post-Translational Peptide Splicing and T Cell Responses
Mishto, M., & Liepe, J. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.011 · Cited by 76
Andersen, R. S., Westergaard, M. C. W., Kjeldsen, J. W., Müller, A., Pedersen, N. W., Hadrup, S. R., Met, Ö., Seliger, B., Kromann‐Andersen, B., Hasselager, T., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0467 · Cited by 73
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Hattori, T., Maso, L., Araki, K. Y., Koide, A., Hayman, J., Akkapeddi, P., Bang, I., Neel, B. G., & Koide, S. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1074 · Cited by 72
Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Hasbullah, H. H., & Musa, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111941 · Cited by 73
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Oya, Y., Imaizumi, K., & Mitsudomi, T. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107886 · Cited by 73
MHC class II restricted neoantigen: A promising target in tumor immunotherapy
Sun, Z., Chen, F., Meng, F., Wei, J., & Liu, B. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.039 · Cited by 73
Bethune, M. T., Li, X., Yu, J., McLaughlin, J., Cheng, D., Mathis, C., Moreno, B. H., Woods, K., Knights, A. J., García-Díaz, Á., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810653115 · Cited by 72
KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma
Gao, G., Liao, W., Ma, Q., Zhang, B., Chen, Y., & Wang, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.004 · Cited by 71
Ma, K.-Y., Schonnesen, A. A., Brock, A., Berg, C. V. D., Eckhardt, S. G., Liu, Z., & Jiang, N. J. (2019) · JCI Insight · doi:10.1172/jci.insight.121387 · Cited by 74
Wang, E., Xiang, K., Zhang, Y., & Wang, X.-F. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.001 · Cited by 56
Lee, J. B., Kang, H., Fang, L., D’Souza, C. A., Adeyi, O. A., & Li, Z. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2291 · Cited by 71
Targeting BRAF and RAS in Colorectal Cancer
Bellio, H., Fumet, J.-D., & Ghiringhelli, F. (2021) · Cancers · doi:10.3390/cancers13092201 · Cited by 71
Tran, E., Longo, D. L., & Urba, W. J. (2017) · New England Journal of Medicine · doi:10.1056/nejme1714680 · Cited by 70
Self-citationType I conventional dendritic cells facilitate immunotherapy in pancreatic cancer
Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Sthanam, L. K., Wang, H., Shalapour, S., et al. (2024) · Science · doi:10.1126/science.adh4567 · Cited by 71
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
Lowery, F. J., Goff, S. L., Gasmi, B., Parkhurst, M. R., Ratnam, N. M., Halas, H. K., Shelton, T. E., Langhan, M. M., Bhasin, A., Dinerman, A. J., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03627-5 · Cited by 71
Self-citationMHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 71
Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations
Choi, J., Goulding, S. P., Conn, B. P., McGann, C. D., Dietze, J. L., Kohler, J., Lenkala, D., Boudot, A. J., Rothenberg, D., Turcott, P. J., et al. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100084 · Cited by 70
Schmidt, J., Chiffelle, J., Perez, M. A. S., Magnin, M., Bobisse, S., Arnaud, M., Genolet, R., Cesbron, J., Barras, D., Rodrigo, B. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38946-z · Cited by 67
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma
Chiffelle, J., Barras, D., Pétremand, R., Orcurto, A., Bobisse, S., Arnaud, M., Auger, A., Rodrigo, B. N., Ghisoni, E., Sauvage, C., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.014 · Cited by 68
Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?
Fan, J., Shang, D., Han, B., Song, J. J., Chen, H., & Yang, J. (2018) · Theranostics · doi:10.7150/thno.29035 · Cited by 67
Quayle, S. N., Girgis, N. M., Thapa, D. R., Merazga, Z., Kemp, M. M., Histed, A., Zhao, F., Moreta, M., Ruthardt, P., Hulot, S. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3354 · Cited by 65
Metadata
- Authors
- Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-08
- Volume
- 375
- Issue
- 23
- Pages
- 2255-2262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5178827
- OpenAlex
- W2559953355
- Cited by
- 1,368
- References
- 27
- Citations by year
- 2026: 96 · 2025: 132 · 2024: 129 · 2023: 162 · 2022: 162 · 2021: 183 · 2020: 149 · 2019: 134 · 2018: 118 · 2017: 98 · 2016: 3
- FWCI
- 71.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010984)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor-infiltrating lymphocytes, mutant KRAS, KRAS G12D, CD8+ T cells, tumor immune evasion, MHC class I loss, cancer immunotherapy
- MeSH terms
- Female, Flow Cytometry, Humans, Lung, Lung Neoplasms, Middle Aged, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
